Breathe Well Live Well
|
Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11
StreetInsider.com “The prevalence of childhood asthma in the U.S. is high, at more than six million patients, and that number continues to rise,” said Dr. Erwin Gelfand, Chairman, Department of Pediatrics at National Jewish Health. “For this young population of asthma … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Albuterol Spiromax; Drug: ProAir HFA; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting – verified July 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Teva sues Perrigo over ProAir asthma inhaler patents
Globes Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) unit Teva Branded Pharmaceutical Products R&D Inc. has filed patent infringement suit with the US District Court for the District of Delaware against Perrigo Company (Nasdaq:PRGO; … |
View full post on asthma – Google News
|
Teva Sues Perrigo Over Patents for Proair Asthma Inhaler
Bloomberg (PRGO) over patents for the ProAir asthma inhaler. Teva Branded Pharmaceutical Products R&D Inc. of Horsham, Pennsylvania, contends Allegan, Michigan-based Perrigo is planning to market its version of the albuterol sulfate aerosol inhaler before the … |
View full post on asthma – Google News